2022-RA-939-ESGO Influence of cancer and surgery to immunosuppressive and proinflammatory factors in ovarian cancer patients’ PBMCs

Abstract

Randomisation is stratified by surgery planned time point (neoadjuvant vs. adjuvant), surgical outcome (R0 vs R1), response to chemotherapy followed by bev (CR/NED vs. PR/ SD) and study center. Primary endpoint is PFS per RECIST v1.1. Secondary endpoints are PFS2, quality of life, daily activity, time to next medical intervention, time to next subsequent therapy, safety assessments and OS. So far 35 patients are randomised in the study.